Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy

Science Translational Medicine

Volumn 9, Issue 386, 2017, Pages

  Yanamandra, Kiran ^a,b   Patel, Tirth K ^a   Jiang, Hong ^a   Schindler, Suzanne ^a   Ulrich, Jason D ^a   Boxer, Adam L ^c   Miller, Bruce L ^c   Kerwin, Diana R ^d   Gallardo, Gilbert ^a   Stewart, Floy ^a   Finn, Mary Beth ^a   Cairns, Nigel J ^a   Verghese, Philip B ^e   Fogelman, Ilana ^e   West, Tim ^e   Braunstein, Joel ^e   Robinson, Grace ^a   Keyser, Jennifer ^a   Roh, Joseph ^a   Knapik, Stephanie S ^e   Hu, Yan ^e   Holtzman, David M ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Foundational Neuroscience Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PRESBYTERIAN HOSPITAL OF DALLAS   (United States)

^e Center for Emerging Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROPROPIONIC ACID; ABBV 8E12; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HJ8.5; TAU PROTEIN; UNCLASSIFIED DRUG; 3-NITROPROPIONIC ACID; ANTIBODY; NITRO DERIVATIVE; PROPIONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SPACE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTERSTITIAL FLUID; MALE; MOUSE; NERVE INJURY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMA HALF LIFE; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TAUOPATHY; TRANSGENIC MOUSE; ANIMAL; BLOOD; BRAIN; DISEASE MODEL; METABOLISM;

ANIMALS; ANTIBODIES; BRAIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; MICE, TRANSGENIC; NITRO COMPOUNDS; PROPIONATES; TAU PROTEINS; TAUOPATHIES;

EID: 85018620802     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aal2029     Document Type: Article

References (51)

1. E.-M. Mandelkow, E. Mandelkow, Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb. Perspect. Med. 2, a006247 (2012).
2. D. N. Drechsel, A. A. Hyman, M. H. Cobb, M. W. Kirschner, Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 3, 1141-1154 (1992).
3. B. Trinczek, J. Biernat, K. Baumann, E.-M. Mandelkow, E. Mandelkow, Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. Mol. Biol. Cell 6, 1887-1902 (1995).
4. A. Probst, D. Langui, C. Lautenschlager, J. Ulrich, J. P. Brion, B. H. Anderton, Progressive supranuclear palsy: Extensive neuropil threads in addition to neurofibrillary tangles. Very similar antigenicity of subcortical neuronal pathology in progressive supranuclear palsy and Alzheimer's disease. Acta Neuropathol. 77, 61-68 (1988).
5. A. Probst, M. Tolnay, D. Langui, M. Goedert, M. G. Spillantini, Pick's disease: Hyperphosphorylated tau protein segregates to the somatoaxonal compartment. Acta Neuropathol. 92, 588-596 (1996).
6. M. Goedert, B. Falcon, F. Clavaguera, M. Tolnay, Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies. Curr. Neurol. Neurosci. Rep. 14, 495 (2014).
7. Y. Saito, N. N. Ruberu, M. Sawabe, T. Arai, N. Tanaka, Y. Kakuta, H. Yamanouchi, S. Murayama, Staging of argyrophilic grains: An age-associated tauopathy. J. Neuropathol. Exp. Neurol. 63, 911-918 (2004).
8. A. de Calignon, M. Polydoro, M. Suárez-Calvet, C. William, D. H. Adamowicz, K. J. Kopeikina, R. Pitstick, N. Sahara, K. H. Ashe, G. A. Carlson, T. L. Spires-Jones, B. T. Hyman, Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73, 685-697 (2012).
9. L. Liu, V. Drouet, J. W. Wu, M. P. Witter, S. A. Small, C. Clelland, K. Duff, Trans-synaptic spread of tau pathology in vivo. PLOS ONE 7, e31302 (2012).
10. A. M. Pooler, E. C. Phillips, D. H. W. Lau, W. Noble, D. P. Hanger, Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 14, 389-394 (2013).
11. K. Yamada, J. K. Holth, F. Liao, F. R. Stewart, T. E. Mahan, H. Jiang, J. R. Cirrito, T. K. Patel, K. Hochgrafe, E.-M. Mandelkow, D. M. Holtzman, Neuronal activity regulates extracellular tau in vivo. J. Exp. Med. 211, 387-393 (2014).
12. K. Yanamandra, N. Kfoury, H. Jiang, T. E. Mahan, S. Ma, S. E. Maloney, D. F. Wozniak, M. I. Diamond, D. M. Holtzman, Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402-414 (2013).
13. A. A. Asuni, A. Boutajangout, D. Quartermain, E. M. Sigurdsson, Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 27, 9115-9129 (2007).
14. A. Boutajangout, J. Ingadottir, P. Davies, E. M. Sigurdsson, Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem. 118, 658-667 (2011).
15. A. Boutajangout, D. Quartermain, E. M. Sigurdsson, Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J. Neurosci. 30, 16559-16566 (2010).
16. D. L. Castillo-Carranza, U. Sengupta, M. J. Guerrero-Muñoz, C. A. Lasagna-Reeves, J. E. Gerson, G. Singh, D. M. Estes, A. D. T. Barrett, K. T. Dineley, G. R. Jackson, R. Kayed, Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J. Neurosci. 34, 4260-4272 (2014).
17. X. Chai, S. Wu, T. K. Murray, R. Kinley, C. V. Cella, H. Sims, N. Buckner, J. Hanmer, P. Davies, M. J. O'Neill, M. L. Hutton, M. Citron, Passive immunization with anti-Tau antibodies in two transgenic models: Reduction of Tau pathology and delay of disease progression. J. Biol. Chem. 286, 34457-34467 (2011).
18. L. Troquier, R. Caillierez, S. Burnouf, F. J. Fernandez-Gomez, M.-E. Grosjean, N. Zommer, N. Sergeant, S. Schraen-Maschke, D. Blum, L. Buee, Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: A suitable therapeutic approach. Curr. Alzheimer Res. 9, 397-405 (2012).
19. S. K. Schroeder, A. Joly-Amado, M. N. Gordon, D. Morgan, Tau-directed immunotherapy: A promising strategy for treating Alzheimer's disease and other tauopathies. J. Neuroimmune Pharmacol. 11, 9-25 (2016).
20. K. Yanamandra, H. Jiang, T. E. Mahan, S. E. Maloney, D. F. Wozniak, M. I. Diamond, D. M. Holtzman, Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann. Clin. Transl. Neurol. 2, 278-288 (2015).
21. Y. Yoshiyama, M. Higuchi, B. Zhang, S.-M. Huang, N. Iwata, T. C. Saido, J. Maeda, T. Suhara, J. Q. Trojanowski, V. M.-Y. Lee, Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351 (2007).
22. D. M. Rissin, D. R. Fournier, T. Piech, C. W. Kan, T. G. Campbell, L. Song, L. Chang, A. J. Rivnak, P. P. Patel, G. K. Provuncher, E. P. Ferrell, S. C. Howes, B. A. Pink, K. A. Minnehan, D. H. Wilson, D. C. Duffy, Simultaneous detection of single molecules and singulated ensembles of molecules enables immunoassays with broad dynamic range. Anal. Chem. 83, 2279-2285 (2011).
23. D. M. Rissin, C. W. Kan, T. G. Campbell, S. C. Howes, D. R. Fournier, L. Song, T. Piech, P. P. Patel, L. Chang, A. J. Rivnak, E. P. Ferrell, J. D. Randall, G. K. Provuncher, D. R. Walt, D. C. Duffy, Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 28, 595-599 (2010).
24. H. Zetterberg, D. Wilson, U. Andreasson, L. Minthon, K. Blennow, J. Randall, O. Hansson, Plasma tau levels in Alzheimer's disease. Alzheimer's Res. Ther. 5, 9 (2013).
25. C. Andorfer, Y. Kress, M. Espinoza, R. de Silva, K. L. Tucker, Y.-A. Barde, K. Duff, P. Davies, Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86, 582-590 (2003).
26. K. Yamada, J. R. Cirrito, F. R. Stewart, H. Jiang, M. B. Finn, B. B. Holmes, L. I. Binder, E.-M. Mandelkow, M. I. Diamond, V. M.-Y. Lee, D. M. Holtzman, In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci. 31, 13110-13117 (2011).
27. E. S. Musiek, D. D. Xiong, T. Patel, Y. Sasaki, Y. Wang, A. Q. Bauer, R. Singh, S. L. Finn, J. P. Culver, J. Milbrandt, D. M. Holtzman, Nmnat1 protects neuronal function without altering phospho-tau pathology in a mouse model of tauopathy. Ann. Clin. Transl. Neurol. 3, 434-442 (2016).
28. B. Spencer, E. Masliah, Immunotherapy for Alzheimer's disease: Past, present and future. Front. Aging Neurosci. 6, 114 (2014).
29. E. Valera, B. Spencer, E. Masliah, Immunotherapeutic approaches targeting amyloid-β, α-synuclein, and tau for the treatment of neurodegenerative disorders. Neurotherapeutics 13, 179-189 (2016).
30. J. T. Pedersen, E. M. Sigurdsson, Tau immunotherapy for Alzheimer's disease. Trends Mol. Med. 21, 394-402 (2015).
31. K. Yamada, T. K. Patel, K. Hochgräfe, T. E. Mahan, H. Jiang, F. R. Stewart, E.-M. Mandelkow, D. M. Holtzman, Analysis of in vivo turnover of tau in a mouse model of tauopathy. Mol. Neurodegener. 10, 55 (2015).
32. 42 in humans. Ann. Neurol. 59, 512-519 (2006).
33. J. H. Roh, Y. Huang, A. W. Bero, T. Kasten, F. R. Stewart, R. J. Bateman, D. M. Holtzman, Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology. Sci. Transl. Med. 4, 150ra122 (2012).
34. R. Potter, B. W. Patterson, D. L. Elbert, V. Ovod, T. Kasten, W. Sigurdson, K. Mawuenyega, T. Blazey, A. Goate, R. Chott, K. E. Yarasheski, D. M. Holtzman, J. C. Morris, T. L. Benzinger, R. J. Bateman, Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci. Transl. Med. 5, 189ra77 (2013).
35. R. B. DeMattos, K. R. Bales, D. J. Cummins, J.-C. Dodart, S. M. Paul, D. M. Holtzman, Peripheral anti-Aβ antibody alters CNS and plasma Ab clearance and decreases brain Ab burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98, 8850-8855 (2001).
36. R. B. DeMattos, K. R. Bales, D. J. Cummins, S. M. Paul, D. M. Holtzman, Brain to plasma amyloid-β efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267 (2002).
37. M. Farlow, S. E. Arnold, C. H. van Dyck, P. S. Aisen, B. J. Snider, A. P. Porsteinsson, S. Friedrich, R. A. Dean, C. Gonzales, G. Sethuraman, R. B. DeMattos, R. Mohs, S. M. Paul, E. R. Siemers, Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 8, 261-271 (2012).
38. A. Asami-Odaka, Y. Obayashi-Adachi, Y. Matsumoto, H. Takahashi, H. Fukumoto, T. Horiguchi, N. Suzuki, M. Shoji, Passive immunization of the Aβ42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease. Neurodegener Dis 2, 36-43 (2005).
39. D. T. Winkler, D. Abramowski, S. Danner, M. Zurini, P. Paganetti, M. Tolnay, M. Staufenbiel, Rapid cerebral amyloid binding by Ab antibodies infused into β-amyloid precursor protein transgenic mice. Biol. Psychiatry 68, 971-974 (2010).
40. J. M. Castellano, R. Deane, A. J. Gottesdiener, P. B. Verghese, F. R. Stewart, T. West, A. C. Paoletti, T. R. Kasper, R. B. DeMattos, B. V. Zlokovic, D. M. Holtzman, Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc. Natl. Acad. Sci. U.S.A. 109, 15502-15507 (2012).
41. J. R. Cirrito, P. C. May, M. A. O'Dell, J. W. Taylor, M. Parsadanian, J. W. Cramer, J. E. Audia, J. S. Nissen, K. R. Bales, S. M. Paul, R. B. DeMattos, D. M. Holtzman, In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J. Neurosci. 23, 8844-8853 (2003).
42. C. d'Abramo, C. M. Acker, J. B. Schachter, G. Terracina, X. Wang, S. K. Forest, P. Davies, Detecting tau in serum of transgenic animal models after tau immunotherapy treatment. Neurobiol. Aging 37, 58-65 (2016).
43. H. Arai, Y-i. Morikawa, M. Higuchi, T. Matsui, C. M. Clark, M. Miura, N. Machida, V. M.-Y. Lee, J. Q. Trojanowski, H. Sasaki, Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem. Biophys. Res. Commun. 236, 262-264 (1997).
44. D. Wagshal, S. Sankaranarayanan, V. Guss, T. Hall, F. Berisha, I. Lobach, A. Karydas, L. Voltarelli, C. Scherling, H. Heuer, M. C. Tartaglia, Z. Miller, G. Coppola, M. Ahlijanian, H. Soares, J. H. Kramer, G. D. Rabinovici, H. J. Rosen, B. L. Miller, J. Meredith, A. L. Boxer, Divergent CSF t alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy. J. Neurol. Neurosurg. Psychiatry 86, 244-250 (2015).
45. R. J. Perrin, A. M. Fagan, D. M. Holtzman, Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461, 916-922 (2009).
46. D. M. Holtzman, J. C. Morris, A. M. Goate, Alzheimer's disease: The challenge of the second century. Sci. Transl. Med. 3, 77sr1 (2011).
47. L. F. Maia, S. A. Kaeser, J. Reichwald, M. Hruscha, P. Martus, M. Staufenbiel, M. Jucker, Changes in amyloid-β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci. Transl. Med. 5, 194re2 (2013).
48. R. B. DeMattos, K. R. Bales, M. Parsadanian, M. A. O'Dell, E. M. Foss, S. M. Paul, D. M. Holtzman, Plaque-associated disruption of CSF and plasma amyloid-β (Aβ) equilibrium in a mouse model of Alzheimer's disease. J. Neurochem. 81, 229-236 (2002).
49. J. M. Castellano, J. Kim, F. R. Stewart, H. Jiang, R. B. DeMattos, B. W. Patterson, A. M. Fagan, J. C. Morris, K. G. Mawuenyega, C. Cruchaga, A. M. Goate, K. R. Bales, S. M. Paul, R. J. Bateman, D. M. Holtzman, Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med. 3, 89ra57 (2011).
50. K. B. J. Franklin, G. Paxinos, The Mouse Brain in Stereotaxic Coordinates (Academic Press, 1997).
51. D. H. Wilson, D. M. Rissin, C. W. Kan, D. R. Fournier, T. Piech, T. G. Campbell, R. E. Meyer, M. W. Fishburn, C. Cabrera, P. P. Patel, E. Frew, Y. Chen, L. Chang, E. P. Ferrell, V. von Einem, W. McGuigan, M. Reinhardt, H. Sayer, C. Vielsack, D. C. Duffy, The Simoa HD-1 Analyzer: A novel fully automated digital immunoassay analyzer with singlemolecule sensitivity and multiplexing. J. Lab. Autom. 21, 533-547 (2016).